Literature DB >> 408319

Reductive cleavage of anthracycline glycosides by microsomal NADPH-cytochrome C reductase.

T Oki, T Komiyama, H Tone, T Inui, T Takeuchi, H Umezawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 408319     DOI： 10.7164/antibiotics.30.613

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  6 in total

1.  Microbial transformation of semisynthetic derivatives of daunomycinone modified in ring A.

Authors:  V Prikrylova; J Jizba; M Blumauerova; J Huk; P Sedmera
Journal:  Folia Microbiol (Praha)       Date:  1989       Impact factor: 2.099

2.  Plasma kinetics of aclacinomycin A and its major metabolites in man.

Authors:  M J Egorin; D Van Echo; B M Fox; M Whitacre; N R Bachur
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Biotransformations of anthracyclinones in Streptomyces coeruleorubidus and Streptomyces galilaeus.

Authors:  M Blumauerová; E Královcová; J Matĕjů; J Jizba; Z Vanĕk
Journal:  Folia Microbiol (Praha)       Date:  1979       Impact factor: 2.099

4.  The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits.

Authors:  N L Harris; D E Brenner; L B Anthony; J C Collins; S Halter; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Sensitive enzyme immunoassay for the quantification of aclacinomycin A using beta-D-galactosidase as a label.

Authors:  M Sohda; K Fujiwara; H Saikusa; T Kitagawa; N Nakamura; K Hara; H Tone
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  An evaluation of hepatic extraction and clearance of doxorubicin.

Authors:  D A August; N Verma; M A Vaertan; R Shah; D E Brenner
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.